Vertex Pharma (VRTX) Tops Q3 EPS by 23c, provides guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $556.75 --0%
Revenue Growth %: +10.7%
Financial Fact:
Net loss: -39.54M
Today's EPS Names:
VIVO, PMCB, PLCE, More
Revenue Growth %: +10.7%
Financial Fact:
Net loss: -39.54M
Today's EPS Names:
VIVO, PMCB, PLCE, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $4.80, $0.23 better than the analyst estimate of $4.57. Revenue for the quarter came in at $3.08 billion versus the consensus estimate of $3.05 billion.
GUIDANCE:
Vertex Pharma sees FY2025 revenue of $11.9-12 billion, versus the consensus of $12.002 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Campbell Soup (CPB) Reports In-Line Q4 EPS, Misses on Revenue; Offers FY27 EPS Guidance
- Broadcom (AVGO) Tops Q3 EPS by 11c, Offers Guidance
- Barrick Gold Corp. (GOLD) PT Lowered to $65 at Canaccord
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
